Factors associated with changes in self-reported health status in infliximab-treated inflammatory bowel disease patients: results from a case management survey. (July 2015)

• Record Type: Journal Article
• Authors: Kanters, Steve; Thorlund, Kristian; Perampaladas, Kuhan; Dyrda, Peter; Williamson, Martin; Jones, Jennifer
• Is Part Of: Expert review of gastroenterology & hepatology. Volume 9:Number 7(2015)
• Page Start: 1015
• Page End: 1021
• Publication Date: 2015-07
• Subjects: Gastroenterology -- Periodicals; Liver -- Diseases -- Periodicals; 616.3
• DOI: 10.1586/17474124.2015.1044977
• Languages: English
• ISSNs: 1747-4124

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p>Background: Canadian inflammatory bowel disease patients treated with infliximab are predominantly managed through a nationwide case management system, named BioAdvance^®. Methods: A web-based survey was provided to patients currently receiving infliximab therapy within BioAdvance^®. Patients were categorized according to health trajectories: decliners, non-changers, moderate increasers and strong increasers. Factors associated with health trajectories were identified using multivariable multinomial logistic regression. Results: 918 of 1160 respondents were inflammatory bowel disease patients reporting health status. Strong increasers were more likely to use educational tools than non-changers (adjusted odds ratio [aOR]: 1.65; 95% CI: 1.03–2.64), to be treated for ulcerative colitis (aOR: 2.05; 95% CI: 1.16–3.64) and to perceive case management as important (aOR: 2.52; 95% CI: 1.56–4.09). Younger (aOR: 0.72; 95% CI: 0.63–0.83) and French-speaking (aOR: 0.34; 95% CI: 0.18–0.63) patients were less likely to miss workdays. Patients were more likely to have missed workdays prior to joining the case management program. Conclusions: Inflammatory bowel disease patients receiving infliximab within the nationwide case management system report a positive impact on health status and absenteeism.</p> </abstract>